{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:02:23Z","timestamp":1787169743168,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Cataract and diabetes, both being a major health care problem, an intervention evaluated for the combination of the two attains paramount importance. The purpose of the study was to determine the role of intraoperative intravitreal dexamethasone implant in patients with diabetic retinopathy with\/without macula edema undergoing phacoemulsification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The study was a two-arm, single-center, randomized, assessor-blinded trial of 151 patients with type-2 diabetes mellitus and cataract. It had two groups: dexamethasone group (DEX) versus standard of care (SOC) group, i.e. phacoemulsification and intraocular lens (IOL) implantation without injection of dexamethasone drug delivery system (DDS). The number of rescue interventions required, central macular thickness by optical coherence tomography (OCT), Early Treatment Diabetic Retinopathy Study (ETDRS) score, laser flare meter (LFM) values, intraocular pressure (IOP), and grade of diabetic retinopathy (DR) were recorded until three months follow up. Macular thickness and number of rescue medications between the treatment groups were the co-primary outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A statistically significant interaction was present between treatment and time on OCT score (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). The requirement of rescue interventions in the dexamethasone DDS group [40.2% (33\/82)] was lesser as compared to the SOC group [49.3% (34\/69)] at the end of 12 weeks [odds ratio (OR), 0.70 (0.36\u20131.33)] follow up although not statistically significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.343). A statistically significant interaction was present between treatment and time on LFM score (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003). No statistically significant interaction was present between the treatment and time on visual acuity score (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.08) and IOP score (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.375).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Dexamethasone implant may have potential as a valuable therapy for patients undergoing cataract surgery with DR with\/without macular edema with effects lasting for at least three months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_749_21","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T12:37:01Z","timestamp":1636634221000},"page":"3263-3272","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Effect of sustained-release long-acting intravitreal dexamethasone implant in patients of non-proliferative diabetic retinopathy undergoing phacoemulsification: A randomized controlled trial"],"prefix":"10.4103","volume":"69","author":[{"given":"Parul Chawla","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagat","family":"Ram","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Kumar-M","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniruddha","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishali","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramandeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema","family":"Bansal","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Katoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangat R","family":"Dogra","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amod","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"B1-20240828","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes:Estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"key":"B2-20240828","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4239\/wjd.v6.i3.489","article-title":"Diabetic retinopathy-ocular complications of diabetes mellitus","volume":"6","author":"Nentwich","year":"2015","journal-title":"World J Diabetes"},{"key":"B3-20240828","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.4103\/ijo.IJO_1240_18","article-title":"Diabetic macular edema:Evidence-based management","volume":"66","author":"Browning","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"B4-20240828","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0886-3350(02)01243-9","article-title":"Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy","volume":"28","author":"Funatsu","year":"2002","journal-title":"J Cataract Refract Surg"},{"key":"B5-20240828","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0886-3350(03)00579-0","article-title":"Occurrence and progression of diabetic retinopathy after phacoemulsification cataract surgery","volume":"30","author":"Hauser","year":"2004","journal-title":"J Cataract Refract Surg"},{"key":"B6-20240828","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/S0886-3350(99)00196-0","article-title":"Cystoid macular edema after phacoemulsification:Relationship to blood-aqueous barrier damage and visual acuity","volume":"25","author":"Ursell","year":"1999","journal-title":"J Cataract Refract Surg"},{"key":"B7-20240828","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archopht.121.1.57","article-title":"Intravitreal injection of triamcinolone for diffuse diabetic macular edema","volume":"121","author":"Jonas","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.ophtha.2006.04.033","article-title":"A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema","volume":"113","author":"Chun","year":"2006","journal-title":"Ophthalmology"},{"key":"B9-20240828","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"B10-20240828","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/ICB.0000000000000414","article-title":"Use of aflibercept for the management of refractory pseudophakic macular edema in irvine-gass syndrome and literature review","volume":"12","author":"Lin","year":"2018","journal-title":"Retin Cases Brief Rep"},{"key":"B11-20240828","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2005.06.007","article-title":"A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema","volume":"112","author":"Cunningham","year":"2005","journal-title":"Ophthalmology"},{"key":"B12-20240828","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.survophthal.2007.12.005","article-title":"Intravitreal steroids for macular edema:The past, the present, and the future","volume":"53","author":"Cunningham","year":"2008","journal-title":"Surv Ophthalmol"},{"key":"B13-20240828","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0161-6420(02)00975-2","article-title":"Intravitreal triamcinolone for refractory diabetic macular edema","volume":"109","author":"Martidis","year":"2002","journal-title":"Ophthalmology"},{"key":"B14-20240828","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0039-6257(04)00109-2","article-title":"Macular edema","volume":"49","author":"Tranos","year":"2004","journal-title":"Surv Ophthalmol"},{"key":"B15-20240828","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ophtha.2012.08.002","article-title":"Dexamethasone intravitreal implant during phacoemulsification","volume":"120","author":"Agarwal","year":"2013","journal-title":"Ophthalmology"},{"key":"B16-20240828","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3:A flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"key":"B17-20240828","first-page":"1352","article-title":"Safety of intravitreal dexamethasone implant (Ozurdex):The safodex study","volume":"37","author":"Malcl\u00e8s","year":"2017","journal-title":"Incidence and risk factors of ocular hypertension. Retina"},{"key":"B18-20240828","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2019.5790","article-title":"Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity:A randomized clinical trial","volume":"321","author":"Baker","year":"2019","journal-title":"JAMA"},{"key":"B19-20240828","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.ophtha.2014.07.002","article-title":"A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema:The Bevordex study","volume":"121","author":"Gillies","year":"2014","journal-title":"Ophthalmology"},{"key":"B20-20240828","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"B21-20240828","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/archopht.125.3.309","article-title":"Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema","volume":"125","author":"Kuppermann","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"B22-20240828","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1097\/IAE.0000000000001364","article-title":"Ocular hypertension after intravitreal dexamethasone (Ozurdex) Sustained-Release Implant","volume":"37","author":"Chin","year":"2017","journal-title":"Retina"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_749_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:12:47Z","timestamp":1787166767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_749_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_749_21","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]},"assertion":[{"value":"2021-04-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}